TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following B-cell leukemias or lymphomas, as defined by World Health Organization criteria:~  * Chronic lymphocytic leukemia/small lymphocytic lymphoma~ * B-cell prolymphocytic leukemia~ * Lymphoplasmacytic leukemia~ * Marginal zone lymphoma (splenic, extranodal, or nodal)~ * Follicular lymphoma (grade 1 or 2)~ * Mantle cell lymphoma~* No more than minimal (approximately 10%) morphologically identifiable cancer cells on bone marrow biopsy~  * When cancer cells are morphologically difficult to distinguish from normal cells, flow cytometry must show no more than 10% identifiable cancer cells~* Must have received ≤ 12 months of prior cytotoxic therapy, achieving at least a partial response NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* WBC ≥ 3,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL~* Platelet count ≥ 75,000/mm\^3~* Serum creatinine ≤ 2.0 mg/dL~* Total bilirubin ≤ 2 mg/dL unless secondary to tumor~* AST or ALT \< 2 times upper limit of normal~* Normal (≥ 45%) left ventricular cardiac ejection fraction (determined by echocardiogram or MUGA scan)~* DLCO \> 50% predicted~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known sensitivity to E. coli-derived products (e.g. filgrastim \[G-CSF\], insulin, asparaginase, growth hormone, or recombinant interferon alfa-2b) or any treatment study drugs~* No active infections requiring oral or intravenous antibiotics~* No other second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix unless the malignancy was localized and treated or resected with \> 90% probability of cure~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior anti-CD20 therapy allowed provided patient achieved a partial or complete response~* No concurrent steroids during rituximab administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- R-HiCy (Type: EXPERIMENTAL): Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 17 years of age~* Are scheduled for uncomplicated unilateral cataract surgery~* Signature of the subject or parent(s) or legally authorized representative on the Informed Consent Form, and when appropriate the minor's assent in accordance with local regulations~* Are willing and able to follow all instructions and attend all study visits~* Are willing to avoid disallowed medication for the duration of the study~* If female is of childbearing potential, agree to and submit a urine sample for pregnancy testing (prior to enrollment and at the end of the study) and use effective contraception for the duration of the study~* Male subjects whose female partners are not post-menopausal must agree to one of the following: 1) completely abstain from sexual intercourse, 2) use a barrier method (condoms) with spermicide during sexual intercourse for the duration of the study, 3) provide documentation for having had a vasectomy (with documented infertility)~* Additional inclusion criteria also apply~Exclusion Criteria:~* Have known sensitivity or poor tolerance to any component of the study drugs~* Have any sign of iritis or scleritis in the study eye~* Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye~* Have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to affect wound healing (e.g., diabetes mellitus, systemic connective tissue disease, severe atopic disease)~* Have known blood dyscrasia or bone marrow suppression~* Have any active corneal pathology in the study eye~* Have had radial keratotomy, corneal transplant, or LASIK in the study eye within the last 2 years~* Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine pregnancy test~* Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device~* Have a condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation~* Use of any medication the investigator feels may interfere with the study parameters~* Additional exclusion criteria also apply

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-305 (Type: EXPERIMENTAL): 0.1% dexamethasone in DuraSite® 2
- Vehicle (Type: PLACEBO_COMPARATOR): DuraSite® 2 Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PD patients with bilateral STN DBS placement and FOG at 130Hz even at usual medication on state.~Exclusion Criteria:~* Known history of recent aspiration pneumonia

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Deep Brain Stimulation (DBS) (Type: EXPERIMENTAL): All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osteogenic Potential of Cissus Quadrangularis Alveolar Ridge Distraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients were included if they were free from any disease that may affect healing. Also, presented with 2-3 missing teeth at least in posterior area and CBCT showed bone height above inferior alveolar canal (IAC) ranged 8-10mm.~Exclusion Criteria:~* patients were excluded if they suffered from any disease affect tissue healing, bad oral hygiene or heavy smoking patients

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
- Group 2 (Type: EXPERIMENTAL): Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate~* Patient must be ineligible for traditional myeloablative transplantation according to treating physician~* Lack of 6/6 or 5/6 HLA-matched related, 8/8 HLA-matched unrelated donor, or unrelated donor not available within a time frame necessary to perform a potentially curative stem cell transplant~* 18-65 years of age~* ECOG Performance Status 0-2~Exclusion Criteria:~* The following hematologic malignancies are excluded:~  * Myelofibrosis unless there has been exposure to cytotoxic chemotherapy for the treatment of progression to acute myeloid leukemia~ * Chronic Myelogenous Leukemia, unless there has been exposure to cytotoxic chemotherapy for the treatment of blast phase, 3) Aplastic anemia, in the absence of transformation to Myelodysplastic disorder~* Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular dysfunction as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension~* Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of \< 50% of predicted, corrected hemoglobin~* Renal disease: serum creatinine \> 2.0mg/dl~* Hepatic disease: serum bilirubin \> 2.0mg/dl (expect in the case of Gilbert's syndrome or ongoing hemolytic anemia), SGOT or SGPT \> 3 x upper limit of normal~* Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation~* HIV antibody~* Uncontrolled infection~* Pregnancy or breast feeding mother~* Inability to comply with the requirements for care after allogeneic stem cell transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): 2 umbilical cord units: Second cord blood unit modulated with ProHema
- Group 2 (Type: ACTIVE_COMPARATOR): 2 umbilical cord units: First cord blood unit modulated with ProHema

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~• Spinal cord injury AIS A,B,C,D~Exclusion Criteria:~* Other central nervous system diseases~* Significant complications that affect spasticity~* Joint contracture~* Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Efficacy of Symbicort® SMART.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.~* Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler~* Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks.~Exclusion Criteria:~* Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.~* Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
- 2 (Type: ACTIVE_COMPARATOR): Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months.~Exclusion Criteria:~* 1.serious disease 2.refuse informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole plus clopidogrel group (Type: ACTIVE_COMPARATOR): esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
- Clopidogrel group (Type: NO_INTERVENTION): clopidogrel 75 mg qd for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female children ≥ 6 years and \< 12 years with confirmed diagnosis of asthma for at least 1 year prior to study enrollment.~* Written informed consent by parent(s)/legal guardian(s) and depending upon their age and local requirements a consent or assent for the patient.~* Patients receiving daily treatment with a stable low dose Inhaled Corticosteroid (ICS) (with or without additional controller), or patients receiving daily treatment with a stable mid-dose ICS (monotherapy or together with LTRA) for at least 4 weeks prior to Screening, and able to tolerate fluticasone propionate 100 μg b.i.d. inhaler starting at Visit 1 (or soon after).~* Patients with a pre-bronchodilator FEV1 ≥ 50% and ≤ 90% of the predicted normal value for the patient at the start and end of Run-in (Visits 101 and 199).~* Patients who demonstrate an increase in FEV1 of 12% within 30 minutes after administration of 400 μg salbutamol/360 μg albuterol (or equivalent dose) at Visit 101. All patients must perform a reversibility test at Visit 101.~Exclusion Criteria:~* Patients taking a mid-dose ICS (per GINA guidelines) in combination with LABA or any patient taking high-dose ICS.~* Evidence of unstable disease within 4 weeks prior to Screening (Visit 1).~* Patients who have had an asthma attack/exacerbation requiring systemic steroids (SCS) or hospitalization or emergency room visit within 3 months prior to Visit 1 (Screening) or more than 3 separate exacerbations in the 12 months preceding Visit 1.~* Suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Screening (Visit 1).~* Prior intubation for asthma.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Indacaterol acetate 75 μg o.d. (Type: ACTIVE_COMPARATOR): Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
- Indacaterol acetate 150 μg o.d. (Type: ACTIVE_COMPARATOR): Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microflare Protocol in Poor Responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females fulfilling the criteria of the ESHRE consensus 2011:~At least two of the following three features must be present:~(i) Advanced maternal age (≥40 years) or any other risk factor for POR; (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).~Exclusion Criteria:~* women who suffer from any other cause of infertility other than poor ovarian reserve~* refusal of the patient to consent for using her data in the study.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Microflare and growth hormone (Type: EXPERIMENTAL): the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
- Microflare protocol alone (Type: NO_INTERVENTION): the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Rapamycin for the Treatment of SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For SLE Subjects:~* SLE patients who exhibit ongoing disease activity by SLEDAI greater or equal to 4.~* SLE patients whose disease activity is controlled by administration of corticosteroids, most commonly, at least 10 mg/day of prednisone.~* 18 years of age or older.~* Updated vaccinations prior to study entry.~* Use of effective contraception for male patients before, during and up to 12 weeks after sirolimus therapy.~For Healthy Control Subjects:~* 18 years of age or older~* Must be matched with one of the SLE patients enrolled in the study by age, gender and ethnic origin~* Must not have any acute or chronic illness.~Exclusion Criteria:~For SLE Subjects:~* Patients who are pregnant.~* Patients with allergy or intolerance to sirolimus.~* Patients with life-threatening manifestations of SLE.~* Patients with proteinuria exceeding 500 mg/24 h or urine protein/creatine ratio \>0.5.~* Patients with total cholesterol \> 300 mg/dl or triglyceride \> 400 mg.dl will be excluded.~* Patients with acute infection requiring antibiotics.~* Patients on sirolimus who develop infections and require intravenous antibiotics and fail to show clinical improvement in 5 days.~* Patients concurrently undergoing B cell-depleting therapy, cyclophosphamide, cyclosporine, and tacrolimus.~* Patients who have received investigational biologic B-cell depleting products within one year of study initiation.~* Patients with a history of chronic viral infections (e.g., HIV, hepatitis B, hepatitis C) or with a history of a malignancy (except non-melanoma skin cancer).~* Due to interference with sirolimus metabolism, subjects will not be allowed to receive concomitant rifampin, ketoconazole,voriconazole, itraconazole, erythromycin, or clarithromycin during the study.~* Patients with any type of interstitial lung disease.~For Healthy control Subjects:~* Subjects who are pregnant.~* Subjects with any acute or chronic illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SLE subjects (Type: EXPERIMENTAL): SLE subjects receiving the study drug, Rapamune.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete